IBTA e-News November 2018 released

By 28th November 2018 December 31st, 2018 News archive
[28 November 2018] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News November 2018 edition in full online here.

Some of the highlights from this month's round-up:

  • The IBTA would like to thank all those who took part in this year’s International Brain Tumour Awareness Week, which ran from 20th-27th October 2018. This year saw a diversity of awareness-raising activities, which included walks, talks and seminars.
  • The UK Parliament ha published a major report which details the financial costs of a brain tumour diagnosis, stating that the average household affected by a brain tumour will be financially worse off by £14,783 (19,000 USD) per year, versus £6,840 for all cancers. The report gives recommendations to reduce financial burden to brain tumour patients and their families, as well as identifying ways to improve patient experience.
  • Research published in Science Translational Medicine has identified the drug digoxin, which is already approved in heart failure treatment, as a possible treatment for subtypes of medulloblastoma. Experiments with digoxin in animals with medulloblastoma subtypes groups 3 and 4 showed an increase in survival
  • Adolescent and young adult brain tumour survivors are at significantly increased risk for symptoms of anxiety, even years after successful treatment for relapse, according to a study published in the Journal of Adolescent and Young Adult Oncology.
  • A new study published in Neuro-Oncology that has examined the outcomes of glioblastoma patients in Finland found that survival in that country has improved between 2000 and 2013. Survival increased from 9.3 months in 2000-2006 to 11.7 months in 2007-2013 in those under 70 years old.
  • Novocure has released results from an analysis of the EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma, which indicate that higher doses of Tumor Treating Fields delivered via Optune to the tumour bed was associated with improved overall survival.
  • Mustang Bio has announced that a phase 1 clinical trial evaluating the safety and effectiveness of a CAR T cell therapy in patients with HER2-positive breast cancer with brain metastases has been initiated. The company has also announced that the first patient has been dosed in a phase 1 clinical trial of HER2-specific CAR T cells in treating recurrent or refractory grade III-IV glioma.
  • Australian charity Cure Brain Cancer Foundation has announced the recipients of its 2018 Innovation Grants program. Two researcher groups have each been awarded AUS$200,000, taking the Foundation’s commitment to brain cancer research to more than $6.5 million over the last five years.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.